8:15–10:15

MORNING SESSION—ASSESSING THE CURRENT STATE OF BIOMARKERS TO PREDICT DRUG-INDUCED TOXICITY.

 

  • What is the current state of the art for screening technologies to find off-target effects early in development—what have we been able to accomplish, and what remains to be done?

  • What are the obstacles impeding progress?

  • How can these efforts be accelerated through public and private means?

Moderator:

MIKHAIL GISHIZKY (Forum Member)

Entelos

8:15–8:30

Overview

ALASTAIR WOOD

Symphony Capital, LLC

8:30–8:45

Cardiac Toxicity

NORMAN STOCKBRIDGE

U.S. Food and Drug Administration

 

DANIEL BLOOMFIELD

Merck Research Laboratories

8:45–9:00

Hepatotoxicity

PAUL WATKINS

University of North Carolina at Chapel Hill

9:00–9:15

Nephrotoxicity

FRANK SISTARE

Merck Research Laboratories

9:15–10:10

Panel Discussion

10:10–10:15

Charge to the Breakout Groups

ROBERT CALIFF (Forum Member)

Duke University Medical Center

10:15–10:30

BREAK



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement